7 Best Peptides for IGF-1 Optimization

What to Know Before Choosing a Peptide for IGF-1 Optimization

IGF-1, or insulin-like growth factor 1, is a hormone the liver produces in response to growth hormone signaling from the pituitary gland. It drives muscle growth, tissue repair, cellular regeneration, and metabolic function, and it declines steadily with age. The interest in optimizing it spans competitive athletes, longevity-focused individuals, people recovering from injury, and anyone trying to support body composition as they get older. Because of that wide appeal, the field of compounds people reach for is broader than most guides acknowledge.

Every compound in this list earned its place by one standard: people use it for IGF-1 optimization, or they are actively discussing using it. That means FDA-approved compounds, telemedicine-prescribed peptides, and research-only chemicals are all eligible, and the strength of a compound's clinical evidence never determines whether it appears here. A compound with robust human trial data and a compound with only community-reported use both belong. The difference is how their evidence is described, not whether they show up. You will see both in this list.

The numbers in front of each entry are an ordering, not a verdict. They reflect how prominently each compound appears in the research and in real-world use for IGF-1 optimization, not a ranking of which compound is better, safer, or more appropriate for any individual person. The right compound for a specific goal, health history, and situation is something the MyPeptidePal app is built to help you work through. This article gives you the lay of the land first.

One field-wide reality worth stating once: most of these compounds are not FDA-approved for the optimization goals people pursue them for, and the human trial data for several of them in healthy adults ranges from limited to nonexistent. That is stated honestly in each entry. It does not mean these compounds are unused or without supporting evidence. It means you need to understand what kind of evidence each one is backed by before deciding what to do next.

1. CJC-1295 with Ipamorelin: The Most Commonly Prescribed Stack

CJC-1295 and Ipamorelin are almost never discussed separately in clinical or community settings, because they are almost never used separately. The combination is the most commonly prescribed IGF-1 optimization protocol in functional medicine and longevity clinics, and understanding why these two compounds work the way they do together matters before looking at either one alone.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, which is the signal the hypothalamus sends to the pituitary to trigger a pulse of growth hormone. By mimicking that signal, CJC-1295 tells the pituitary to release more GH. Because elevated GH then prompts the liver to produce IGF-1, CJC-1295 raises IGF-1 indirectly, through the body's own axis rather than by introducing a foreign hormone. CJC-1295 is available in two forms: one with a drug affinity complex that binds to albumin in the blood and extends its half-life considerably, and one without it, which acts over a shorter window and produces sharper pulses.

Ipamorelin is a growth hormone secretagogue that works at a different receptor, the ghrelin receptor on the pituitary, to trigger a pulse of GH release. It is widely considered the cleanest of its class because it does not meaningfully spike cortisol or prolactin the way older growth hormone releasing peptides did, which matters for long-term tolerability. When CJC-1295 and Ipamorelin are combined, the two act on complementary receptors and the resulting GH pulse is larger than either produces alone, which translates to a more significant and sustained elevation of IGF-1.

The clinical profile of this combination is better than most compounds in this list but still falls short of large-scale randomized controlled trial evidence in healthy adults for optimization purposes. CJC-1295 and Ipamorelin are used off-label through compounding pharmacies and telemedicine platforms, and clinicians favor the combination precisely because it preserves the pituitary's natural feedback loops rather than bypassing them. Users across clinical and community settings consistently report improvements in body composition, recovery, sleep quality, and lean mass over sustained use. The evidence here is primarily off-label clinical use, practitioner observation, and user-reported experience rather than large published trials designed for healthy adult optimization.

2. Tesamorelin: The Most Clinically Validated Option

Tesamorelin occupies a unique position in this field because it is the only compound in the GH secretagogue class with FDA approval. It is approved specifically for HIV-associated lipodystrophy, a condition involving abnormal visceral fat accumulation, and its mechanism, binding to GHRH receptors on the pituitary to stimulate GH release and downstream IGF-1 production, is the same mechanism the whole secretagogue class uses. The difference is that tesamorelin has a body of randomized controlled trial data behind it that the other compounds in this category do not.

Because the approval is for a specific condition and not for general optimization, off-label use in longevity and functional medicine falls outside the approved indication. Tesamorelin is available through compounding pharmacies under physician supervision, and clinicians working in longevity settings increasingly use it for its dual profile: it raises IGF-1 through GH stimulation while simultaneously reducing visceral fat, a combination not cleanly replicated by the other secretagogues. That visceral fat effect is considered distinctive to tesamorelin among the GHRH analogues and is one reason it has gained traction in anti-aging and metabolic health settings beyond its original indication.

Its safety profile is the most extensively studied of any compound in this list within its class. The clinical trial population for the approved indication is large enough that the adverse event picture is well characterized, with fluid retention, glucose changes, and injection site reactions as the most commonly reported concerns. For IGF-1 optimization specifically, the evidence base is the off-label clinical use literature and practitioner-reported outcomes rather than trials designed for that goal, but the underlying pharmacology is the same as what was studied in the approved trials. Among all the secretagogues discussed here, tesamorelin carries the strongest clinical foundation, which is why it sits high in this ordering.

3. MK-677: The Oral Option with Human Trial Data

MK-677, also known as ibutamoren, is not technically a peptide. It is a small molecule that mimics ghrelin and binds to the ghrelin receptor on the pituitary, which triggers the release of growth hormone and, downstream, raises IGF-1. It is included in almost every serious discussion of IGF-1 optimization because its oral route of administration makes it practically distinct from everything else in this space, and because it has genuine human clinical trial data showing it raises GH and IGF-1 levels in treated populations.

Published clinical studies in older adults demonstrate that MK-677 increases IGF-1 levels into ranges typically seen in younger adults, and serious adverse effects were not reported in those trial populations. That combination of oral convenience and actual human data places MK-677 in a stronger evidence position than many of the injectable research chemicals people also use for this goal. The studies were not conducted in healthy young adults pursuing optimization, so the trial population does not perfectly match many of its current users, but the pharmacology is directly relevant and the data exists.

The tradeoffs are real. MK-677 stimulates appetite considerably, which users consistently report, and water retention is a commonly noted effect. It is not FDA-approved for optimization use and is typically sold as a research chemical outside of clinical contexts. Some users run it for extended periods because of the oral convenience and the sustained IGF-1 elevation it provides. Clinicians and community users alike reach for it when injection-free IGF-1 support is the goal. The evidence here is a mix of published human trial data for the mechanism and user-reported experience for the optimization application specifically.

4. Sermorelin: The Conservative Entry Point

Sermorelin is a synthetic version of the first 29 amino acids of human growth hormone-releasing hormone, making it the most structurally native of the GHRH analogues discussed here. It is FDA-approved, but only for diagnosing growth hormone deficiency in children, not for adult optimization. Its off-label use in functional medicine as a first-line option for adults seeking to raise IGF-1 is widespread, and it is frequently the compound clinicians recommend for people who are new to GH axis support, given its lower potency relative to tesamorelin and CJC-1295 and its well-characterized safety profile.

The mechanism is the same as the other GHRH analogues: sermorelin stimulates the pituitary to release growth hormone, which then drives the liver to produce more IGF-1. Because its potency is lower, it is less likely to push IGF-1 levels past target ranges, which is why it is often described as the conservative entry point and why clinicians using it typically monitor IGF-1 levels during use. The lower ceiling on IGF-1 elevation is both its limitation and its safety argument.

Human evidence for sermorelin's GH-stimulating effect is well established from its approved diagnostic use. Evidence for its role as an adult optimization tool comes from off-label clinical practice and practitioner-reported outcomes rather than large optimization-specific trials. Users across clinical settings report modest improvements in body composition, sleep quality, and recovery over time, outcomes consistent with what the mechanism predicts. Controlled trial evidence in healthy adults for optimization purposes is not what the sermorelin literature covers, but sermorelin is a real, widely used option for conservative IGF-1 support and its place here reflects that.

5. IGF-1 LR3: The Direct Analog for Advanced Use

IGF-1 LR3 is structurally modified IGF-1, not a secretagogue. Rather than stimulating the pituitary or liver, it directly activates the IGF-1 receptor on target tissues, bypassing the entire GH axis. The structural modification involves changes at the N-terminus and in the E-domain region that prevent the peptide from binding to IGF-binding proteins, which are the proteins that sequester roughly 98% of native IGF-1 in circulation and render it inactive. By evading that sequestration, IGF-1 LR3 remains biologically active for a far longer window than native IGF-1, which has a half-life measured in a few hours under normal conditions.

That extended bioavailability combined with direct receptor activation is why IGF-1 LR3 is discussed for goals that go beyond what secretagogues can achieve: maximum hypertrophy, nutrient partitioning, localized muscle growth when injected intramuscularly, and the long-discussed but unconfirmed possibility of hyperplasia, which is the creation of new muscle cells rather than simply enlarging existing ones. The compound also activates the mTOR signaling pathway, which drives protein synthesis and inhibits the breakdown of muscle tissue, producing an anti-catabolic effect that users in anabolic-focused communities value highly.

There is no published human clinical trial data for IGF-1 LR3 used for optimization or performance purposes in healthy adults as of 2026. What exists is user-reported experience across community protocols, primarily from bodybuilding and advanced biohacking circles, alongside preclinical data on the pharmacokinetics and receptor biology. The compound is not FDA-approved for human use and is classified as a research chemical. It is also prohibited by WADA, which matters for competitive athletes. Community users consistently flag hypoglycemia as the primary immediate risk, a predictable consequence of IGF-1's insulin-like signaling at the cellular level. This is an advanced compound with a meaningful safety profile, not a beginner-accessible option, and its position in this list reflects genuine widespread community use rather than an endorsement of that use.

6. IGF-1 DES: For Localized Muscle Targeting

IGF-1 DES, sometimes written as DES 1-3 IGF-1, is a truncated form of IGF-1 with the first three amino acids removed from the N-terminus. That truncation eliminates the region responsible for binding to IGF-binding proteins, which means almost none of it is sequestered in circulation. The result is a very high concentration of free, biologically active peptide at the injection site, which is both its primary advantage and the reason it is used differently from IGF-1 LR3.

Where IGF-1 LR3 produces a prolonged systemic effect because it circulates actively for an extended window, IGF-1 DES has a half-life measured in minutes. It is used specifically for localized effects: community protocols call for injecting it directly into the target muscle immediately before training that muscle, with the intent of amplifying local anabolic signaling in a specific tissue rather than producing a body-wide response. The local potency at the IGF-1 receptor in that immediate window is considerably higher than native IGF-1 or LR3, because the free fraction represents nearly the entire dose rather than a small percentage of it.

Like IGF-1 LR3, IGF-1 DES has no published human clinical trial data for optimization or performance use as of 2026. Its evidence base is entirely community-reported, drawn from bodybuilding protocols where it is often used alongside IGF-1 LR3 as complementary tools for systemic versus local signaling. It is a research chemical with no FDA approval for human use. Its inclusion here reflects the fact that people actively use and discuss it for this goal, and that its mechanism is meaningfully different from LR3 in a way that warrants a separate entry for anyone mapping the full landscape.

7. GHRP-2 and GHRP-6: Older Secretagogues Still in Active Use

GHRP-2 and GHRP-6 are older growth hormone releasing peptides that were widely used before Ipamorelin became the dominant compound in that class. They work by binding to the ghrelin receptor on the pituitary, triggering a pulse of growth hormone release that drives downstream IGF-1 production, the same basic mechanism as Ipamorelin. They remain in active use in community protocols and appear in IGF-1 optimization discussions frequently enough that leaving them off the list would leave a real gap for readers who have already encountered them.

The practical reason Ipamorelin largely displaced them in clinical settings is the side effect profile. GHRP-6 reliably stimulates appetite to a significant degree and produces cortisol and prolactin spikes alongside the GH pulse. For users who prioritize clean GH release without those hormonal side effects, that profile is unfavorable for long-term use. GHRP-2 has a somewhat different picture but still produces more cortisol stimulation than Ipamorelin. Hexarelin, another older GHRP sometimes grouped with these two, produces a potent GH pulse but carries the highest side-effect burden in the class and is less commonly used in contemporary protocols.

The evidence base for GHRP-2 and GHRP-6 is a mix of older research establishing the GH-stimulating mechanism and user-reported experience from community protocols. There are no large human optimization trials for these compounds in healthy adults as of 2026. They are research chemicals sold outside clinical channels. Community users who still run them, often paired with CJC-1295 or IGF-1 LR3 in more aggressive stacks, cite effective GH pulse induction and cost as the primary reasons. For most use cases related to IGF-1 optimization, Ipamorelin has effectively replaced them in both clinical and informed community practice, but they belong in this overview because they remain part of the real-world conversation.

How These Peptides Compare

Frequently Asked Questions

What is the difference between raising IGF-1 indirectly and using a direct analog?

Indirect secretagogues like CJC-1295, Ipamorelin, and tesamorelin stimulate the pituitary and liver to produce more of the body's own IGF-1, which means the natural feedback loops that regulate GH and IGF-1 levels stay in place. Direct analogs like IGF-1 LR3 and IGF-1 DES skip that axis entirely and activate the IGF-1 receptor without going through the pituitary or liver, which produces stronger and more direct signaling but removes those regulatory checks. Most clinicians favor the secretagogue route for ongoing use because it works with the body's existing system rather than around it.

Are these compounds legal to buy and use?

The answer depends on the specific compound and how it is obtained. Tesamorelin and sermorelin have FDA approval for specific medical indications and can be prescribed off-label through licensed physicians and compounding pharmacies. MK-677, CJC-1295, Ipamorelin, IGF-1 LR3, and IGF-1 DES are not FDA-approved for optimization use and are typically sold as research chemicals outside of clinical channels. Competitive athletes should note that several of these compounds are prohibited under WADA rules, and legal status varies by country.

Do IGF-1 optimization peptides carry cancer risk?

This is a real concern that deserves a direct answer. IGF-1 signaling promotes cellular growth and proliferation, which is what makes it interesting for muscle and tissue goals and what raises legitimate questions about its relationship to cancer biology. Animal studies have shown associations between elevated IGF-1 and tumor growth, and there is a theoretical risk in humans that most clinicians take seriously. Most physicians recommend that people with a personal or strong family history of certain cancers avoid these compounds and discuss the question with a qualified healthcare provider before considering any protocol.

How is the CJC-1295 and Ipamorelin combination typically obtained?

In clinical settings, the CJC-1295 and Ipamorelin combination is the most commonly prescribed IGF-1 optimization stack and is available through compounding pharmacies with a physician's prescription. Telemedicine platforms specializing in hormone optimization and peptide therapy have made access more straightforward in recent years. Outside clinical channels, both compounds are sold as research chemicals, though that route comes without the quality verification and medical oversight that a compounding pharmacy under physician supervision provides.

What does the term "research chemical" mean in practical terms?

A research chemical is a compound sold legally for laboratory or scientific research purposes and labeled as not for human use. This designation means the compound has not cleared the regulatory process required for pharmaceutical sale, which includes rigorous testing for purity, sterility, and safety. In practice, many people do use research chemicals for personal goals, but without the quality controls that apply to compounded or pharmaceutical-grade products. Experienced community users consistently note that adverse experiences often trace back to source quality rather than the molecule itself.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for IGF-1 optimization in one place.